ArticlePloS one2025
Association of biological age acceleration with all-cause and cardiovascular mortality in HSV-positive adults: A population-based longitudinal cohort study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TyG Index and Obesity-Related Measures in Relation to All-Cause Mortality Among HSV-Positive Adults.International journal of endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiological age acceleration reflects physiological aging and its link to mortality in HSV-infected adults is unclear.
methodsWe analyzed data from 16,065 HSV-seropositive adults aged 20-59 years from the NHANES 1999-2016 cycles (mean age: 35.4 ± 8.5 years). The data were collected in the United States. Biological age acceleration and Phenotypic age acceleration were calculated as residuals from regressing KDM-based biological age and PhenoAge on chronological age, respectively. The mean (SD) values were -10.9 (10.4) and -3.4 (4.6) years. Over a median follow-up of 139 months, 551 all-cause and 131 cardiovascular deaths occurred. Weighted Cox proportional hazards models were used to evaluate associations between biological age acceleration and mortality. Nonlinear associations and potential threshold effects were assessed using smooth curve fitting based on generalized additive models. Subgroup and sensitivity analyses confirmed the robustness of the results.
resultsBoth biological age acceleration and Phenotypic age acceleration were significantly associated with increased all-cause and cardiovascular mortality. Among individuals with Phenotypic age acceleration > -1.8, each 5-year increase was associated with a 68% higher risk of all-cause mortality (HR: 1.68; 95% CI: 1.47-1.92; P < 0.001). For biological age acceleration > 3.14, each 5-year increase was associated with a 16% higher risk (HR: 1.16; 95% CI: 1.03-1.30; P = 0.0133). Results remained consistent across subgroups and in sensitivity analyses.
conclusionIn a cohort of HSV-seropositive adults in the United States, biological age acceleration, particularly Phenotypic Age acceleration, was significantly associated with increased risks of all-cause and cardiovascular mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.